Black checkmark with a sparkle and a curved line underneath on a white background.
Company

QT IMAGING HOLDINGS, INC.

Ticker
QTI
Sector
Industry
Report date
November 11, 2026
Valye AI Score

91

Very high visibility
Recent developments
Recent developments summary

Recent developments include multiple quarterly earnings call transcripts in 2026 providing operational insights, appointment of a new CFO in 2025, insider share purchases, and investor presentations highlighting innovative technology and strategic direction.

Recent developments:
  • QT Imaging held its Q3 2026 earnings call, providing updates on operational progress and financial results [N1].
  • The company conducted its Q2 2026 earnings call, discussing business developments and technology advancements [N3].
  • QT Imaging released Q1 2026 earnings call highlights, outlining recent milestones and strategic initiatives [N4].
  • Jay Jennings was appointed as the new CFO of QT Imaging Holdings in August 2025 [N6].
  • The chairman of QT Imaging purchased 2,671,232 shares in March 2025, indicating insider confidence [N7].
  • QT Imaging highlighted its innovative breast imaging technology and AI-enabled platform in an investor presentation in March 2026 [N5].
Overview

QT Imaging Holdings, Inc. is a medical device company specializing in innovative breast imaging technology that uses low-energy sound waves to generate high-resolution, volumetric 3D images of breast tissue. The technology avoids ionizing radiation and breast compression, aiming to improve patient comfort and diagnostic accuracy, particularly for women with dense breast tissue or at intermediate to high risk of breast cancer. The company’s Breast Acoustic CT scanner has received FDA 510(k) clearances, including recent enhancements to improve imaging coverage near the chest wall. QT Imaging is developing a cloud-based SaaS platform to deliver AI-driven quantitative imaging biomarkers and diagnostic decision support, positioning itself as a precision imaging platform combining hardware, software, and cloud AI modules. The company targets both traditional tertiary care hospitals and decentralized, low-resource environments, emphasizing affordability, ease of use, and improved patient experience. QT Imaging faces challenges typical of development-stage companies, including limited operating history, ongoing net losses, and the need to demonstrate commercial viability at scale. The company also faces risks related to share dilution and geopolitical instability affecting distribution channels.

Executive summary

QT Imaging Holdings, Inc. develops and commercializes a novel breast imaging technology using low-energy transmitted sound to produce high-resolution 3D volumetric images without ionizing radiation or breast compression. The company’s Breast Acoustic CT scanner has received FDA 510(k) clearances, including enhancements for improved imaging coverage. QT Imaging is building a cloud-based SaaS platform integrating AI for quantitative imaging biomarkers and diagnostic support, aiming to transition from hardware manufacturing to a precision imaging platform. As of September 30, 2026, the company reported net losses and negative cash flow but maintains liquidity with a current ratio of 2.78. Risks include limited operating history, challenges in scaling commercial viability, competitive industry pressures, potential dilution from share sales, and geopolitical risks affecting distribution in the Middle East. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. [S1][S2]

Scenarios for QTI

Bull case model:

QT Imaging’s innovative breast imaging technology addresses critical unmet needs by providing radiation-free, comfortable, and quantitative 3D imaging, potentially improving diagnostic accuracy and patient adherence to screening programs. The company’s strategy to evolve into a precision imaging platform with AI-driven cloud services could create new revenue streams and enhance clinical insights. Its technology’s suitability for decentralized and low-resource environments expands market reach beyond traditional hospital settings. Successful commercialization and adoption could establish QT Imaging as a disruptive player in breast imaging, with potential for strong revenue growth and improved healthcare outcomes.

Bear case model:

QT Imaging faces significant risks as a development-stage company with limited operating history and ongoing net losses. The commercial viability of its breast imaging platform at scale remains unproven, and manufacturing cost challenges could impede business model execution. Market acceptance is uncertain in a competitive medical imaging industry dominated by established modalities. Potential dilution from extensive share and warrant issuances may pressure stock price and investor sentiment. Geopolitical instability in key distribution regions could disrupt supply chains and revenue generation. Failure to overcome these challenges could impair the company’s ability to achieve profitability or sustain operations.

Moat:

QT Imaging’s moat is based on its proprietary, non-ionizing breast imaging technology that offers a unique combination of high-resolution volumetric 3D imaging without radiation or compression, addressing significant limitations of current breast cancer screening modalities. The company’s FDA-cleared Breast Acoustic CT scanner and its planned AI-enabled cloud SaaS platform for quantitative imaging biomarkers create a differentiated product ecosystem. The technology’s portability, operator-independent workflow, and suitability for low-resource and point-of-care settings further enhance its competitive positioning. However, the moat is challenged by the company’s limited operating history, the need to scale manufacturing and commercialization, and competition from established imaging modalities and companies.

Risks overview
Risks summary
The biggest risks for QT Imaging include its limited operating history with unproven commercial scalability, ongoing financial losses, competitive market challenges, potential dilution from share sales, and geopolitical instability affecting distribution.
Risks details:

• Limited Operating History and Commercial Viability: QT Imaging has a limited operating history and has demonstrated commercial viability only at small scales. The company may face challenges in scaling manufacturing and achieving cost-effective production to support its business model.
• Ongoing Net Losses and Negative Cash Flow: The company has incurred significant net losses and negative cash flow since inception, with accumulated deficits increasing over time. Continued losses may affect liquidity and ability to finance operations.
• Market Acceptance and Competition: QT Imaging operates in a highly competitive medical imaging industry. Its technology and business model may not achieve widespread market acceptance, limiting revenue generation.
• Share Dilution and Market Price Pressure: Significant resale registration statements and outstanding warrants create potential for dilution and downward pressure on the stock price due to sales by existing stockholders and warrant holders.
• Geopolitical Risks: Distribution arrangements in the Middle East expose the company to risks from ongoing military conflicts and geopolitical instability, which could disrupt supply chains, increase costs, and impair revenue from these regions.

FINAL FORECAST FOR QTI

Final take one line
QT Imaging Holdings, Inc. is a development-stage medical device company with a proprietary breast imaging technology and evolving AI-enabled platform, characterized by detailed public disclosures and ongoing operational updates but facing typical early-stage risks.
Final take 12 to 24 month view

Business trends: Development and commercialization of a novel non-ionizing breast imaging technology with FDA clearances and expansion into AI-driven cloud SaaS platforms.
Execution milestones: Progress in regulatory clearances, quarterly earnings updates, CFO appointment, and investor presentations highlighting technology and strategy.
Key risks: Limited operating history and commercial scalability, ongoing financial losses, competitive market acceptance challenges, share dilution risks, and geopolitical instability affecting distribution.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

91
LLM visibility overview
LLM Visibility known facts
  • QT Imaging Holdings, Inc. is a medical device company focused on research, development, and commercialization of innovative body imaging systems using low energy sound, specifically for breast imaging [S1].
  • The company’s core technology is a novel body imaging platform producing high-resolution volumetric 3D images of breast tissue using low-energy transmitted sound waves, avoiding ionizing radiation and breast compression [S1].
  • QT Imaging’s Breast Acoustic CT scanner is a Class II medical device cleared by the FDA under multiple 510(k) clearances, including enhancements for improved imaging coverage near the chest wall [S1].
  • The company is developing a cloud-based SaaS platform integrating AI and machine learning for quantitative imaging biomarkers and diagnostic decision support, aiming to evolve from hardware manufacturing to a precision imaging platform combining hardware, software, and cloud AI modules [S1].
  • QT Imaging targets breast cancer screening and diagnosis, aiming to improve patient experience, reduce costs, and provide enhanced imaging especially for women with dense breast tissue and intermediate to high risk profiles [S1].
  • The company’s technology is designed for operator-independent imaging workflow, improving reproducibility and enabling deployment in low-resource environments and point-of-care settings [S1].
  • QT Imaging has a history of net losses and negative cash flow since inception, with accumulated deficits and continuing operating losses as of September 30, 2026 [S2].
  • As of September 30, 2026, the company had $8.12 million in cash and equivalents, current assets of $28.2 million, current liabilities of $10.16 million, resulting in a current ratio of 2.78 and a cash ratio of 0.8, indicating liquidity coverage [S2].
  • The company faces risks including limited operating history, unproven commercial viability at scale, potential inability to manufacture cost-effectively, and challenges in achieving market acceptance [S2].
  • QT Imaging operates in a competitive medical imaging industry and may face difficulties in generating significant revenues or achieving profitability [S2].
  • The company’s shares have significant resale registration statements outstanding, with potential for dilution and market price pressure from sales by existing stockholders and warrant holders [S2].
  • Geopolitical risks include exposure to Middle East conflicts affecting distribution in Saudi Arabia and UAE, with potential supply chain disruptions and increased costs [S2].
  • Recent operational updates include multiple quarterly earnings call transcripts in 2026 and appointment of a new CFO in 2025 [N1][N3][N4][N6].
  • The company has highlighted its innovative technology and strategic focus on AI-enabled imaging platforms in investor presentations [N5].
  • Insider activity includes a significant share purchase by the chairman in 2025 [N7].
Sources
Sources - Context summary

Generated 2026-11-11

Sources - Earning calls
  • N1
  • N3
  • N4
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-25 | 10-K
  • S2 | 2026-11-10 | 10-Q
Sources - News headlines
  • N1 | 2026-11-11 | www.nasdaq.com | QT Imaging (QTI) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/qt-imaging-qti-q3-2026-earnings-call-transcript
  • N2 | 2026-09-08 | www.nasdaq.com | Vaso Gains More Than 65% in Three Months: What's Driving the Stock? | https://www.nasdaq.com/articles/vaso-gains-more-65-three-months-whats-driving-stock
  • N3 | 2026-08-13 | www.nasdaq.com | QT Imaging (QTI) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/qt-imaging-qti-q2-2026-earnings-call-transcript
  • N4 | 2026-05-14 | www.nasdaq.com | QT Imaging Q1 Earnings Call Highlights | https://www.nasdaq.com/articles/qt-imaging-q1-earnings-call-highlights
  • N5 | 2026-03-25 | www.nasdaq.com | QT Imaging Highlights Innovative Technology in Investor Presentation | https://www.nasdaq.com/articles/qt-imaging-highlights-innovative-technology-investor-presentation
  • N6 | 2025-08-28 | www.nasdaq.com | QT Imaging Holdings Appoint Jay Jennings As New CFO | https://www.nasdaq.com/articles/qt-imaging-holdings-appoint-jay-jennings-new-cfo
  • N7 | 2025-03-25 | www.nasdaq.com | Insider Purchase: Chairman of $QTI Buys 2,671,232 Shares | https://www.nasdaq.com/articles/insider-purchase-chairman-qti-buys-2671232-shares
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine